Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab and Apatinib with HAIC and Systemic Chemotherapy in Unresectable Biliary Tract Cancer
NCT07569679Phase 2Recruiting
- Sponsor
- Air Force Medical University
- Start
- Dec 2025
- Primary completion
- Dec 2028
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of adebrelimab, Rivoceranib in biliary tract cancer (BTC), sponsored by Air Force Medical University. Started Dec 2025; status: recruiting.
02
Drugs
adebrelimabRivoceranib
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT07569679.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07569679.